Cogent Biosciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Cogent Biosciences, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 90% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 85% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-127.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 85% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-170.9×Operating cash was negative last year, while some debt falls due within a year.
Lower than 90% of Healthcare companies in United States.
Cash Cushion Ratio
+12%Cash, after subtracting all debt, equals 12% of its market value (net cash).
Higher than 54% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Cogent Biosciences, Inc. made a loss over the last year. Cogent Biosciences, Inc. owes $0.36 for every $1 it owns. Cogent Biosciences, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCogent Biosciences, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
10.17The share price is 10.17 times Cogent Biosciences, Inc.'s book value per share, higher than 87% of Healthcare companies in United States.
Market cap
$5.4 BThe total market value of all of Cogent Biosciences, Inc.'s shares at today's price (share price × number of shares), larger than 85% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$532 MWhat Cogent Biosciences, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$3.07Net worth divided by the number of shares. The share price of $31.21 is 10.2 times this, which is the P/B above.
Return on equity (ROE)
-109.7%Cogent Biosciences, Inc. lost 109.7% of its shareholders' money over the last year, lower than 73% of Healthcare companies in United States.
Owes vs Owns
0.36×Cogent Biosciences, Inc. owes $0.36 for every $1 it owns (low), lower than 54% of Healthcare companies in United States.
Dividend yield
NoneCogent Biosciences, Inc. does not currently pay a dividend.
Profit growth
LossCogent Biosciences, Inc. made a loss in each of the last two years.
Interest cover
Not coveredCogent Biosciences, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashCogent Biosciences, Inc. held $662 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Cogent Biosciences, Inc.: $5.4 B ÷ $532 M (30 Jun 2026) = 10.2.
What is Cogent Biosciences, Inc.'s return on equity?
Cogent Biosciences, Inc. lost 109.7% of its shareholders' money over the last year, lower than 73% of Healthcare companies in United States.
How much does Cogent Biosciences, Inc. owe compared with what it owns?
Cogent Biosciences, Inc. owes $0.36 for every $1 it owns (low), lower than 54% of Healthcare companies in United States.
Does Cogent Biosciences, Inc. pay a dividend?
No. Cogent Biosciences, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.